Literature DB >> 1370524

A chemically defined synthetic vaccine model for HIV-1.

B Nardelli1, Y A Lu, D R Shiu, C Delpierre-Defoort, A T Profy, J P Tam.   

Abstract

Multiple Ag peptide (MAP) system without the use of a protein carrier was used as a vaccine model in three species of animals. Synthetic peptides from the V3 region of the gp120 of IIIB, RF and MN HIV-1 isolates were used as the Ag. MAP consisting of various chain lengths, from 11 to 24 residues, were prepared in a monoepitope configuration containing four repeats of each individual peptide. In parallel, they were synthesized in a diepitope configuration adding at the carboxyl-terminus of the V3 peptides a conserved sequence, known to be a Th cell epitope of gp120. The antibody response elicited by the monoepitope constructs was species-dependent. Rabbits produced immunity against all nine peptides, whereas mice were strongly reactive mainly to the longest sequence of the IIIB isolate. The immune response of guinea pigs was intermediate to those of rabbits and mice. Diepitope MAPs were immunogenic in all three species and elicited significantly higher titers than those raised by the immunization with the monoepitope MAPs. The response was type specific; the high-titered antibodies were reactive mostly against the isolate from which the peptides were derived, with a small cross-reactivity in ELISA between IIIB and RF strains. The dominant antigenic site of the B cell epitope, IIIB sequence, was located at the amino and central part of the MAP and a sequence overlapping the putative V3 reverse-turn was particularly reactive with the raised antibodies. Moreover, sera from the immunized animals inhibited virus-dependent cell fusion. These results show that MAP, with a chemically defined structure and without the use of a protein carrier, can be potentially useful for the design of synthetic HIV-1 vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370524

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide.

Authors:  B Nardelli; J P Tam
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

2.  Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.

Authors:  N Yahi; J Fantini; K Mabrouk; C Tamalet; P de Micco; J van Rietschoten; H Rochat; J M Sabatier
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

3.  SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.

Authors:  N Yahi; J Fantini; S Baghdiguian; K Mabrouk; C Tamalet; H Rochat; J Van Rietschoten; J M Sabatier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

4.  Macromolecular assemblage in the design of a synthetic AIDS vaccine.

Authors:  J P Defoort; B Nardelli; W Huang; D D Ho; J P Tam
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 5.  Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Authors:  Zhi-Hua Huang; Zhan-Yi Sun; Yue Gao; Pu-Guang Chen; Yan-Fang Liu; Yong-Xiang Chen; Yan-Mei Li
Journal:  Vaccines (Basel)       Date:  2014-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.